Vor to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Vor Biopharma (Nasdaq: VOR), a leader in cell and genome engineering, will participate in three virtual investor conferences. The events include a Fireside Chat at the Morgan Stanley Global Healthcare Conference on September 10, 2021, a presentation at the H.C. Wainwright Investment Conference from September 13-15, 2021, and a presentation at the Oppenheimer MedTech Summit on September 22, 2021. Attendees can access live webcasts and archived replays via the Company's website, enhancing investor outreach and information availability.

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today announced that the Company will be participating in three upcoming virtual investor conferences:

Morgan Stanley Virtual 19th Annual Global Healthcare Conference
Fireside Chat Date: Friday, September 10, 2021
Time: 2:00 PM ET

H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13^th through Wednesday, September 15^th, 2021

Oppenheimer’s Virtual Fall Healthcare Life Sciences & MedTech Summit
Presentation Date: Wednesday, September 22, 2021
Time: 3:45 PM ET

The fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference and presentation at the Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit will be webcast live. A pre-recorded webcast of the presentation at the H.C. Wainwright 23rd Annual Global Investment Conference will be made available on Monday, September 13, 2021, at 7:00 AM ET. All of the webcasts can be accessed via the Investors section of the Company's website at www.vorbio.com. An archived replay of each webcast will also be available.

About Vor Biopharma
Vor Biopharma is a cell and genome engineering company that aims to transform the lives of cancer patients by pioneering an engineered hematopoietic stem cell (eHSC) therapeutic platform that unlocks the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancer cells while sparing healthy cells.

Contacts:

Investors:
Chris Brinzey
Westwicke, an ICR Company
+1 339-970-2843
chris.brinzey@westwicke.com

Media:
Rebecca Spalding
Ten Bridge Communications
+1 646-509-3831
rebecca@tenbridgecommunications.com

FAQ

What investor conferences is Vor Biopharma participating in September 2021?

Vor Biopharma will participate in the Morgan Stanley Global Healthcare Conference on September 10, H.C. Wainwright Investment Conference from September 13-15, and Oppenheimer MedTech Summit on September 22.

When is Vor Biopharma's fireside chat at the Morgan Stanley Conference?

The fireside chat at the Morgan Stanley Virtual Global Healthcare Conference is scheduled for September 10, 2021, at 2:00 PM ET.

How can I watch Vor Biopharma's presentations?

You can watch Vor Biopharma's presentations live via webcasts, available through the Investors section of their website.

What is Vor Biopharma's focus as a company?

Vor Biopharma focuses on cell and genome engineering to develop engineered hematopoietic stem cell therapies aimed at transforming cancer treatment.

When will the pre-recorded webcast for the H.C. Wainwright Conference be available?

The pre-recorded webcast for the H.C. Wainwright Conference will be available on September 13, 2021, at 7:00 AM ET.